Venus Remedies announces successful renewal of its European certification

Share it

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable oncology formulations. Shares of Venus Remedies Ltd ended at ₹296.20, down by ₹3.35, or 1.12%, on the BSE.

Leave a Comment

Your email address will not be published. Required fields are marked *